ArticleCancer research communications2025
A First-In-Human Dose-Escalation Phase I Study of Basroparib, a Tankyrase Inhibitor, in Patients with Advanced-Stage Solid Tumors.
Article in Cancer research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04505839 (First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors
Who cites it
2 citing papers in PubMed.
- Replacement soaking for human tankyrase 2 enables studies on substrate analogues and inhibitors.Acta crystallographica. Section D, Structural biology · 2026Article
- Basroparib inhibits YAP-driven cancers by stabilizing angiomotin.Molecular oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeThe pathogenesis of colorectal cancer is largely driven by mutations of the tumor suppressor gene APC (adenomatous polyposis coli) that lead to aberrant activation of the β-catenin-dependent (canonical) Wnt signaling pathway. We evaluated basroparib, a tankyrase-selective inhibitor targeting the Wnt/β-catenin signaling pathway, in a first-in-human phase I clinical study for safety, tolerability, pharmacokinetics, and efficacy in patients with advance-stage solid tumors. PATIENTS AND
methodsPatients enrolled to this open-label, multicenter study (NCT04505839) were treated with basroparib capsules orally once daily in 28-day cycles (21-day on and 7-day off) in dose escalation at seven dose levels (30-360 mg) following the classic "3 + 3" design.
resultsTwenty-five patients (colorectal cancer, 23 patients; male sex, 48%, and median age, 58 years) were treated with basroparib. Dose-limiting toxicities and fatal treatment-related adverse events were not observed. The most commonly reported treatment-related adverse events were fatigue and nausea with mild/moderate severity. Basroparib pharmacokinetics increased less than proportionally with dose increase up to 300 mg. Among 17 patients evaluated for response, four (23.5%) had stable disease with a duration of up to 2.5 months and relative higher drug exposure compared with others. The dose of 360 mg was determined to be the maximum tolerated dose and recommended phase II dose.
conclusionsBasroparib was shown to be a safe and well-tolerated tankyrase-selective inhibitor with preliminary antitumor activity warranting further investigation. SIGNIFICANCE: Tankyrase in the active β-catenin-dependent (canonical) Wnt signaling pathway has been a desirable but difficult target because of safety concerns. We developed a tankyrase-selective inhibitor, basroparib, and successfully introduced it in a first-in-human study. This study demonstrated a favorable safety profile and modest antitumor activity for basroparib and suggests that basroparib may play a role when combined with other rational targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.